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Abstract
Background and hypothesis: Chronic Obstructive Pulmonary Disease (COPD) patients are characterized by
heterogeneous clinical manifestations and patterns of disease progression. Two major factors that can be used to
identify COPD subtypes are muscle dysfunction/wasting and co-morbidity patterns. We hypothesized that COPD
heterogeneity is in part the result of complex interactions between several genes and pathways. We explored the
possibility of using a Systems Medicine approach to identify such pathways, as well as to generate predictive
computational models that may be used in clinic practice.
Objective and method: Our overarching goal is to generate clinically applicable predictive models that
characterize COPD heterogeneity through a Systems Medicine approach. To this end we have developed a general
framework, consisting of three steps/objectives: (1) feature identification, (2) model generation and statistical
validation, and (3) application and validation of the predictive models in the clinical scenario. We used muscle
dysfunction and co-morbidity as test cases for this framework.
Results: In the study of muscle wasting we identified relevant features (genes) by a network analysis and
generated predictive models that integrate mechanistic and probabilistic models. This allowed us to characterize
muscle wasting as a general de-regulation of pathway interactions. In the co-morbidity analysis we identified
relevant features (genes/pathways) by the integration of gene-disease and disease-disease associations. We further
present a detailed characterization of co-morbidities in COPD patients that was implemented into a predictive
model. In both use cases we were able to achieve predictive modeling but we also identified several key
challenges, the most pressing being the validation and implementation into actual clinical practice.
Conclusions: The results confirm the potential of the Systems Medicine approach to study complex diseases and
generate clinically relevant predictive models. Our study also highlights important obstacles and bottlenecks for
such approaches (e.g. data availability and normalization of frameworks among others) and suggests specific
proposals to overcome them.
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Recent years have seen a paradigm shift in Life Sciences:
“from a fragmented to a systems approach, linear to non-
linear methodology and from genome to physiome based
analysis” [1]. Systems Medicine, as an adaptation and
extension of Systems Biology, embraces this paradigm
and is becoming a cornerstone in the study of complex
diseases. A general introduction to Systems Medicine is
provided in [2]. In this article, part of a Supplement
dedicated to the Synergy-COPD project [2], we review
and assess the Synergy-COPD’s Systems Medicine
approach to study Chronic Obstructive Pulmonary Dis-
ease (COPD), both a chronic and a complex disease.
While the characterization of COPD has been exten-
sively investigated and there is a continuous refinement of
guidelines (e.g. GOLD), there is yet no consensus on a
phenotypic definition of the term “COPD patient”.F o r
instance in [3] several sub-types of COPD patients were
identified; see also [4] within this Supplement for further
details on the heterogeneity in COPD. Briefly, within
Synergy-COPD we aim to characterize two sources of het-
erogeneity: first we investigated the systemic effects asso-
ciated with skeletal muscle dysfunction in COPD patients
(MusclDYS). Second, we aimed to characterize co-morbid-
ity patterns of COPD patients (CoMorb). Finally, we also
investigated the interplay between the different heteroge-
neities, which may provide a novel description of COPD
as being driven by the interaction between several factors.
Using COPD as a case-study we explore the notion that
Systems Medicine provides tools to investigate and charac-
terize disease heterogeneity. To this end our analyses
follow a general three-step procedure: (1) first, we need to
identify the relevant biomarkers (or more generally
features of interest, FoI) for each case of heterogeneity; (2)
in a second step, predictive models with the potential to
be applied in the clinic are developed and validated statis-
tically. Third and final, (3) the usefulness of the models in
a clinical scenario has to be validated. To achieve this goal
we integrated a wide variety of available resources, such as
prior domain knowledge, relevant data-bases and existing
probabilistic and mechanistic models.
The rest of this article is organized as follows: the next
section details the Systems Medicine framework used in
Synergy-COPD. The third and fourth sections describe
the application of this framework in the characterization
of MusclDYS and CoMorb. These sections include a
brief description of the questions, the obtained results
and the limitations of the proposed methodology. The
final section provides the conclusions and summarizes
the identified remaining challenges.
The Synergy-COPD’s systems medicine approach
Systems Medicine provides a comprehensive and general
framework to investigate the complex interactions
implicated in human disease in an integrated fashion.
Consequently, there is no single defined set of meth-
odologies associated with Systems Medicine. Instead,
any methodology useful to investigate the question
under study “as a system” can be considered as relevant
to explore and validate. While the concrete focus of
Synergy-COPD lay on COPD, we aimed at developing a
more general framework that may also be applicable to
other complex diseases. We therefore started by defining
a generic three-step objective plan that sets the goals in
our studies of MusclDys and CoMorb (Figure 1). The
plan was then concretized and adapted to each question
accordingly.
Our final goal was a characterization of the disease
heterogeneities that can be transferred to clinical prac-
tice (Figure 1, Objective 3), in particular by implement-
ing it into a Clinical Decision Support system (CDSS,
[5]). The first step (Objective 1) towards this goal is to
identify the relevant, i.e. most predictive, biological fea-
tures among the large amount of available data, e.g.
genes, metabolites and clinical variables, among many
others. The second step (Objective 2) is to integrate
these features into predictive models and to validate
them. In the following we briefly review each objective
for the two case studies MusclDys and CoMorb and
introduce the respective different resources and meth-
odologies that were used.
Objective 1, (Biomarker identification): having defined
a question of interest (e.g. MusclDys) we first need to iden-
tify the relevant associated features. The core of this
Objective is formed by publicly available data-sets and
knowledge (e.g. Gene Omnibus [6]) that were integrated
into a user-friendly knowledge-base [7]. The different
methodologies for MusclDys and CoMorb are detailed in
two separate sections.
Objective 2 (Predictive modeling): the identified fea-
tures are now used in predictive models that may provide
insights into the question of interest. For instance, in
MusclDys we aim to predict the effects of muscle dysfunc-
tion in a given patient. In CoMorb we aim to compute the
probability of developing a specific co-morbidity in COPD
patients. Those quantitative models are question-specific
and require both statistical (e.g. through cross-validation
[8]) and biological validation.
Objective 3 (Clinical application):b r i d g i n gt h eg a p
between a predictive model and its use in clinical prac-
tice constitutes an important and challenging task:
Beyond the basic statistical and biological validation of a
model, it also needs to be clinically relevant in the con-
text of personalized medicine. In this objective, predic-
tive models are reviewed for their possible uses in a
CDSS. Once a model is considered useful in principle,
both a thorough clinical validation and an optimal
CDSS implementation are required.
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(MusclDys) through systems medicine
Objective 1: Biomarker identification
To identify the relevant features associated with muscle
dysfunction/wasting we used existing data and knowl-
edge through (existing and novel) network-based meth-
odologies. We considered the Biobridge clinical study
[2] as the core of the data and extended it through pub-
licly available data-sets from GEO [6]. Among the most
relevant data-sets are the gene expression profiling of
sputum in COPD ex-smokers (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE22148) and Peripheral
Blood Mononuclear Cell (PBMC) profiling of COPD
patients by COPDgene [9]. For those data-sets used but
not publicly available we had permission to access and
analyze the data. Next we describe the interactome-
based methodologies and results.
The Interactome
The etiology of COPD involves a multitude of inter-
twined molecular processes, many of which still remain
unknown. These processes are embedded in the larger
context of the Interactome,r e f e r r i n gt oas i n g l ec o m -
prehensive network integrating all molecular interac-
tions, such as protein-protein interactions, regulatory
protein-DNA interactions or metabolic interactions (see
Figure 2). While ongoing efforts to systematically map
the complete Interactome stand only at the beginning,
currently available databases (Table 1) already include
several hundreds of thousands of interactions. In order
to explore such large networks, Systems Medicine has
extensively adopted tools from network science [10-12].
Network approaches to human disease are based on the
observation that the cellular components associated
with a specific disease are not scattered randomly within
the Interactome, but segregate in certain neighborhoods
or disease modules. The identification of the specific
disease modules is therefore an important step towards
a holistic understanding of how molecular variations
with small isolated effect sizes collectively give rise to a
certain disease phenotype. The local agglomeration of
disease-associated proteins within the Interactome can
be used in this process, by extrapolating from the con-
nectivity patterns of known disease-associated proteins
to infer novel disease proteins [13,14]. Other applica-
t i o n so ft h i sp r i n c i p l ei n c l u d e the identification of path-
way members [15] or prioritization of weak GWAS loci
[16]. In [17] a COPD specific protein interaction net-
work was constructed around genes differentially
expressed between healthy and COPD subjects. This
network was then queried for potential drug targets that
could reverse the expression changes. COPD specific
gene expression is also the basis of a Systems Medicine
method proposed in [18] that aims at identifying sub-
groups of COPD patients with different molecular
signatures.
Typically, only direct physical (binding) interactions are
considered in the Interactome. Another line of Systems
Medicine network approaches uses functional networks,
where links may also represent indirect associations, for
example co-expression [19] or genetic interaction
[20,21]. These networks are usually assembled from spe-
cific experimental data, rather than the more general
Figure 1 Synergy-COPD’s Systems Medicine framework.
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use of functional networks in COPD is given by the study
of [22]. In order to explore the molecular basis of muscle
degeneration in COPD, they developed a network model
integrating several types of relevant measurements, such
as blood cytokine levels and muscle gene expression.
They were thereby able to identify several tissue remodel-
ing and bioenergetics pathways that fail to coordinate in
COPD diseased muscles.
Both physical and functional-based networks are use-
ful tools that allow the identification of de-regulated
functional elements, and to zoom-in into the interac-
tions driving that de-regulation. We considered this
information to be relevant in the generation of predic-
tive models addressing the characterization of heteroge-
neity in COPD.
Methodologies and results
To characterize skeletal muscle dysfunction in COPD
patients before and after training we evaluated two
hypotheses. In the first hypothesis, MusclDys is charac-
terized by the de-regulated activity of a selected set of
pathways; namely transcription, proteolysis, immune
activation and/or oxidative phosphorylation (see [4] for
more details). Using these pathways as a reference an
initial list of associated genes was downloaded from the
Synergy-COPD Knowledge-base SKB [7] and then fil-
tered by clinical and biological experts. We followed a
network approach similar to one described in the Bio-
Bridge analysis [22] and extended it by including differ-
ential expressed genes, metabolites, cytokines, and
clinical variables in addition to the filtered list of genes.
We generated a network for each combination of
healthy vs COPD and untrained vs trained individuals,
obtaining two main results. First, we identified a module
(i.e. a network-based cluster of genes, Mod1) that is pre-
sent in all networks and shows the interaction between
mRNA-translation, Insulin and mTOR pathways. Inter-
estingly, this module was also associated to immune
Figure 2 Mechanistic Models and extensions. (a) Oxygen transport and utilization model (M1). (b) Mitochondrial respiration and reactive-
oxygen species generation model (M2). (3) Personalized model of M2: M2 model is personalized by a Bayesian network that predicts the values
of UQCR2 (oxidative phosphorylation chain) by inflammation-associated measurements (IL11RA and TNFRSF25). All models can be simulated in
the Simulation Environment [58] and the patient specific values can be obtained through a COPD Knowledge Based [7].
Table 1 Major resources for protein interaction data:
Database / Interaction type Reference
Databases integrating several sources IntAct [59], MINT [60], BioGRID [61], HPRD [62], MIPS [63], STRING [64]
Protein complexes: CORUM [65], [66]
Binary interactions (high-throughput) CCSB-HI (CCSB), [67;68]
Regulatory interactions TRANSFAC [69]
Kinase-substrate Interactions PhosphositePlus [70]
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loss of co-regulation (including Mod 1l o s s )i nC O P D
patients’ muscle after training, independently confirming
[22]. These promising results require further corroborat-
ing data in order to obtain a robust predictive model.
In a second hypothesis, we considered that given the
relevance of bioenergetics and immune markers in
COPD patients, we could use them to explain the level
of Reactive Oxidative Species (ROS, major markers of
oxidative stress) in COPD patients’ muscle. In order to
identify the sub-network(s) linking immune and bioe-
nergetics genes to ROS-associated genes (from [23;24])
in the context of COPD we developed a chain-based
methodology [25] named ChainRank. Briefly, the metho-
dology identifies relevant sub-networks by identifying
and scoring chains of interactions that link specific tar-
gets. The type of interactions to include in the chain
search are selected by the user; we selected among those
interactome-networks included in the Synergy-COPD
Knowledge-Base [7]. Scores are generated from the inte-
gration of multiple general and context specific mea-
sures. Finally, the algorithm allows the identification of
genes that are over-represented in highly ranked chains
as relevant features. This list was then used for generat-
ing personalized predictive models in Objective 3.
Objective 2: Predictive models
The generation of predictive models in MusclDys
involves three steps, beginning with the identification of
existing mechanistic models that were then updated and
adapted to better estimate particular features of interest
(FoI). In this process we make use of Objective 1’s
results to either identify FoI or to personalize the mod-
els by adding disease-related parameters.
The identification of mechanistic existing models
Many phenomena in physiology and biology are of
essentially nonlinear nature and therefore require quan-
titative descriptions in addition to qualitative ones [26].
We considered three well-described physiological mod-
els of interest to the characterization of COPD: (i) Oxy-
gen transport and utilization [27,28] (M-OX); (ii) Cell
Bioenergetics, mitochondrial respiration and reactive-
oxygen-species generation (ROS) [23,24], (M-ROS); and,
(iii) Spatial heterogeneities of lung ventilation and perfu-
sion [29] (M-HET). The first two models (M-OX and M-
ROS) are relevant for the characterization of the sys-
temic effects of the disease in skeletal muscle, as they
provide mechanistic description of both the oxygen
pathway and ROS generation. The third model (M-
HET) is relevant for the study of pulmonary events in a
sub-set of COPD patients [3] with low pulmonary den-
sity (high emphysema score) and mild airway remodel-
ing resulting in mild to moderate airflow limitation.
Oxygen transport and utilization [27,28](M-OS): The
model details the determinants of oxygen transport
from air to mitochondria and characterizes oxygen utili-
zation at mitochondrial level during maximum exercise.
In summary, it constitutes the most complete integrative
approach of the interplay among factors modulating
oxygen transport (lungs, hearth, blood and skeletal
Figure 3 The “Disease Interactome”. The Interactome (left) represents the complex network of all molecular components (gene products, proteins,
metabolites, RNAs etc.) and their interactions. Diseases can be understood as local perturbations. The local neighborhood around genes reported to
be associated with COPD (right) is only a very small subset of the full Interactome, yet already shows its enormous complexity.
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(a)). In COPD patients, the oxygen transfer capacity from
the atmosphere to the cell, as well as its utilization at mito-
chondrial level, can be limited. It is therefore of interest to
observe the effects of such a limitation at all levels of the
transport chain [30] and, in particular, its effects on
muscle’sm i t o c h o n d r i a .
Cell Bioenergetics, mitochondrial respiration and reac-
tive-oxygen-species generation (M-ROS): The model
details mitochondrial respiration and its relation with
the production of Reactive Oxidative Species (ROS).
The model integrates two sub-models, the Electron
Chain model and the TCA cycle module [23,24]. ROS
production in the mitochondrial respiratory chain is a
signal of cellular adaptation to the environment, but a
sharp increase is incompatible with cell survival; there-
fore the predicting ROS production is a relevant task.
Moreover, in smoking-related COPD patients the anti-
oxidant capacity is severely reduced and further
decreases after smoking cessation due to endogenous
production of ROS [31,32]. The integrated model
(M-OX + M-ROS) generated within the Synergy-COPD
project allows estimating quantitatively the relationships
between determinants of cell oxygenation and mito-
chondrial ROS generation. The interplay between ROS
levels and the antioxidant capacity of the redox system
ultimately determines tissue oxidative and nitrosative
stress with important implications on pathway regula-
tion and cell damage.
Spatial heterogeneities of lung ventilation and perfu-
sion [29] (M-HET): The anatomy-based multi-scale
model of the human pulmonary circulation allows for
the study of pre- and post-occlusion flow and embolus-
generated blow flow redistribution, among other fea-
tures. It combines four independent simulations of
model geometry, tissue mechanics, ventilation and blood
flow allowing for a local description of alveolar ventila-
tion and pulmonary blood flow. The lung modeling
approaches are described in this Supplement in detail in
a separate paper as interactive work with the FP7 EU
Project AirPROM. A major relevance of lung modeling
in Synergy-COPD is the characterization of patients
with reduced lung density but without classical COPD
symptoms of airway obstruction [3]. The inclusion of
this modeling approach in Synergy-COPD had two main
goals. Firstly, the analysis of the impact of spatial het-
erogeneities of lung ventilation and perfusion on blood
oxygenation and, secondly, the study of the subset of
COPD patients showing dissociation between high
emphysema score and low intensity of airway remodel-
ing, as indicated above and described in [3].
Updating existing models
In order to characterize skeletal muscle dysfunction in
COPD (MusclDys) we modified the oxygen transport
and utilization model (M-OX) and included the mito-
chondrial respiration [33]. The outcomes of this model
were two fold: (1) it increased the physiological validity
of the model by estimating the mitochondrial PO2,( 2 )i t
allowed for the integration with bioenergetics models
(M-ROS). A second extension of the model was the
modeling of lung ventilation/perfusion heterogeneities
and [33]; these extensions (see Figure 2(a)) allows better
estimation and better personalization of the model in
COPD.
In addition, we integrated models M-OX and M-ROS
(IM) to model the relation between oxygen transport and
ROS generation, which constitutes a major marker of
skeletal muscle dysfunction. Parameter models were
investigated again in the case of [23,24], to provide better
ROS estimations. A major outcome of the integrated
model analysis [34] is that it permits to estimate the
effect of various states of oxygen supply and demand of
mitochondrial PO2 on ROS production; this is relevant in
COPD patients with airway obstruction symptoms [22].
Novel models
In Synergy-COPD we generated novel models (Objective
2) by integrating existing mechanistic models, developed
for the healthy individual, with features of interest (FoI)
associated to MusclDys (obtained in Objective 1).
Having identified ROS as a major marker of muscle
dysfunction, we aimed to predict ROS status by surro-
gate variables identified in Objective 1. Initially those
surrogate variables were immune markers from protein
measurements in the blood as shown in [22]. To inte-
grate the effect of the surrogate variables (SV) with the
integrated model of oxygen transport and ROS genera-
tion we proposed to use SV values (which are more
commonly used in clinical diagnostics) to estimate a
subset of the integrated model parameter values. As a
technical solution we proposed the used of Bayesian
networks (see Figure 2(c), [35]) to connect immune
markers and selected model parameters. This connec-
tion was also possible through the use of methodologies
and results obtained during Objective 1 such as the
ChainRank methodology briefly described elsewhere in
the manuscript. However, the generation of accurate
linking-by-Bayesian networks is limited by the require-
ment of a large number of samples. Therefore, to
i n c r e a s ea c c u r a c yw em a d eu s eo fp u b l i ca v a i l a b l em u s -
cle-related data-sets in GEO [6] and included estimates
of relations from other sources such as text-mining
[36]) into the Bayesian network generation. While we
considered that the proposed approach to be technically
valid, still we need to increase the sample size to gener-
ate useful models, therefore the requirement of follow-
up studies. The model can be run in the Synergy-COPD
Simulation Environment and the patient specific values
can be obtained through a COPD Knowledge Base [2,7].
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data from muscle biopsies and literature-based data into
a mathematical discrete model [37]. By this model-dri-
ven approach we aimed to determine the processes that
lead the abnormal adaptation to training in COPD
patients and the role of ROS in this process. Since skele-
tal muscle mitochondrial dysfunction is a central actor
in COPD [38] this approach was based on those genes
associated to selected mitochondrial processes from
Objective 1’s candidate biomarkers obtained in [22]. The
modeling was achieved by inferring the activity state of a
gene regulatory network (GRN) in six different states:
Control group, COPD with normal body mass index
(BMI) and COPD with low BMI before and after under-
going 8 weeks of training program [22]. We carried out
this task in two parts: 1) GRN reconstructions and 2)
Integration of GRN into a discrete model.
As a first step in the GRN reconstruction we curated
the list of candidate biomarkers to be included by the
re-analysis of the transcriptomic data of the six different
states used previously in [22]. For this aim, we used sta-
tistical methods such as rank product [39] to determine
the gene candidates and Gene Ontology and Human
Proteins Atlas databases [40,41] to filter those genes
associated with mitochondrial processes in skeletal mus-
cle. Next, to determine gene associations we used IPA
software and DroID [42,43]. Finally, In order to correct
incomplete or erroneous annotations and identify the
direction and the sign of the interactions, we manually
curated the GRN reconstruction using a large number
of bibliographic data sources.
The GRN reconstruction was then converted into a
mathematical discrete model based on the Thomas form-
alism [44] by mechanistically describing the interactions
between those mitochondrial-associated genes that were
differentially expressed between states. In order to refine
the accuracy of our model predictions, we used public
available muscle-related data-sets in GEO [6] to impose
constraints to our model. We integrated these constraints
in the form of inequalities based on probabilistic
approaches: if we observed a strong Pearson correlation
(rho>0.9) between two non-connected genes, their
expression values were forced to evolve in the same
direction. The rationale is just the opposite in the case of
a strong anti-correlation. Then, summing up, we propose
a method by which the interaction between genes are
determined by performing a tissue and organelle specific
GRN reconstruction and the constraints are defined
using probabilistic approaches, finally both, the GRN
reconstruction and the constraints are integrated into a
discrete model in order to unveil the mechanisms gov-
erning the adaptation to training in the groups of study.
Together, both probabilistic approaches show a way
forward to close the inherent under-determination gap
of deterministic, quantitative models by coupling data
driven and knowledge driven approaches.
Objective 3: Clinical application and limitations in
Synergy-COPD
The models proposed to address MusclDys are still far
from the clinical practice. We consider that the methodol-
ogies to achieve such goal do exist, but the data publicly
available is limited. Several lessons can be learnt:
(1) While the use of mechanistic models is very valid
to understand biological systems and diseases, they
have serious limitations in the study of complex
diseases. Complex diseases may be described as the
combination of many factors, and mechanistic mod-
els will require too many parameters and conse-
quently too much data to be yet clinically effective.
(2) However statistical predictive models (e.g. linear
models, Bayesian networks, etc.), not necessarily
mechanistically accurate, may provide a valid technical
solution. The implementation of such technical solu-
tion requires the use of large amount of data to ensure
accuracy and statistical validation. For this data to be
obtained we consider necessary (1) to strengthen the
policies promoting data-sharing (especially in the clini-
cal context) and (2) the generation of large data-sets
with proper experimental designs and clinically-driven
hypotheses.
(3) Clinically driven research needs to be re-designed
to align the different objectives described in Figure 1.
We observed that the re-use of data is necessary but
complex, and minimal modifications (such as extended
questionnaires to patients providing samples) in exist-
ing bio-banks may be very useful.
Understanding COPD co-morbidities through
systems medicine
COPD has been associated with several diseases such as
lung cancer [45], metabolic syndrome and cardiovascular
diseases [46]. However, not all COPD patients share the
same diseases or exhibit the same degree of co-morbidity.
We hypothesized that the particular co-morbidities in a
given COPD patient can be understood from his/her parti-
cular set of de-regulated pathways and genes. Identifying
genes and pathways that are shared between COPD asso-
ciated diseases could therefor ea l l o wf o ram o r ed e t a i l e d
characterization of COPD and its co-morbidities. In the
first subsection we briefly describe our method to identify
such potential biomarkers (pathways and/or genes). We
then introduce our initial predictive models in the second
subsection and finally discuss the clinical applications.
Some of the data sets supporting this article are available
in HuDiNe repository (http://barabasilab.neu.edu/projects/
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mission to access and analyze the data.
Biomarker and Co-morbidity identification
Using 13 million health records from U.S. Medicare
[47], we identified 27 disease groups (DG) with signifi-
cantly elevated risks to co-occur with COPD. These
groups included both well-established associations like
cardiovascular diseases or lung cancer, but also unex-
pected ones that could be interesting candidates for
more focused follow-up investigations. In order to eluci-
date possible shared molecular origins between the dis-
ease groups and COPD, we considered their respective
implicated pathways: for each disease group, we first
constructed a comprehensive list of known associated
genes from the literature (by pooling several sources of
gene-disease associations such as OMIM, NIH The-
saurus and text-mining among others). We then per-
formed a pathway enrichment analysis for each disease
group. The results show that there are a number of
pathways that are shared between different disease
groups, suggesting that the observed co-morbidities are
indeed rooted in shared molecular mechanisms. By
further inspecting the genes within prevalent pathways
we were able to identify a number of genes with the
potential to characterize COPD co-morbidity. We are
investigating if those markers may predict the level of
co-morbidity. This could be of immediate relevance for
the clinical practice, as co-morbidity has been associated
to lower overall quality of life [48] and increased mortal-
ity [47,49]. To date, a number of interesting outcomes of
this analysis remain to be validated in further studies.
H o w e v e r ,w i t hc u r r e n t l ya v a i l a b l ed a t aw ec o n s i d e r e d
that the disease groups and co-factors such as age and
gender could be used to generate predictive models.
Predictive models
We selected disease groups that are highly prevalent in
COPD patients, such as heart and circulation associated
diseases and digestive alterations. The observation that
their prevalences vary with age prompted us to develop
a first model (Objective 2) aiming to predict the prob-
ability for specific co-morbidities in COPD patients over
different age strata; in this case we made use of the
ranking of co-morbidities from Objective 1 to select
those diseases of major interest in the generation of the
predictive models. This model may be used as support
information for clinicians in the daily practice (e.g. pre-
dictive medicine, or comparing observed symptoms with
candidate co-morbidities). For a more robust clinical
validation, however, follow-up studies in different
cohorts will be required; for this reason we consider the
comorbidity modeling as part of Objective 2, but closer
to the Objective 3 that any other model presented.
Clinical application and limitations in Synergy-COPD
While co-morbidity is being generally accepted as a rele-
vant clinical factor [47,50-55], co-morbid predictive models
are rarely reaching the clinical practice. Our experiences
gained throughout the Synergy-COPD project suggest sev-
eral limitations:
(1) Incompatibilities in the medical nomenclature.
While there are several large health registries available
to investigate co-morbidities (e.g. Medicare, Swedish
Registry and others), there is yet to agree a common
diagnostic standard even for simplified administrative
coding. In Sweden, for instance, nowadays ICD10 is
being used, yet the registry also includes information
coded in ICD7 to ICD9. In comparison, Medicare (as
used in [47]) is mainly using ICD9 codes. Maps
between ICD coding do exist, but they are not accu-
rate, and every new ICD coding system may represent
a different conceptual approach. ICD11 will represent
a new challenge.
(2) There are many studies investigating specific co-
morbidities, not only in COPD but in many other dis-
eases. Yet, two major limitations inhibit the integration
of these studies in larger meta-analyses: (1) diseases
may be defined differently in each study and in many
cases no official coding is followed; (2) the selection of
diseases is biased towards well established and
expected diseases. These two limitations reflect that
most studies are developed to validate specific hypoth-
eses. We believe that broader studies and normalized
questionnaires will eventually facilitate meta-analyses
and thereby increase the power of co-morbidity
studies.
(3) Finally, previous large-scale studies are often lim-
ited to one type of data: either -omics data were col-
lected, but no co-morbidity information, or the other
way round. We believe that in the future it will be cru-
cial to combine these two approaches.
Conclusions
Despite the massive amounts of data collected in medical
research throughout the last decades, our understanding
of complex diseases still remains very limited. The funda-
mental shortcoming of our knowledge may be illustrated
by a popular quote attributed to Ernest Rutherford: all
science is either physics or stamp collecting [56]. Systems
Medicine bears the promise of facilitating the transition
from stamps to understanding. Indeed we are convinced
that a systems perspective is necessary for the integration
of all hitherto largely disconnected facts, thereby ulti-
mately enabling clinically predictive tools. Synergy-COPD
presents a large-scale case study of Systems Medicine
applied to COPD, recognizing that both Clinical Research
Gomez-Cabrero et al. Journal of Translational Medicine 2014, 12(Suppl 2):S4
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integrative quantitative models. Developing such models is
a complex task which we addressed by adhering to a
3-step framework: (1) feature identification, (2) model gen-
eration and statistical validation, (3) clinical validation and
implementation. We developed and used the framework
targeting specifically the characterization of muscle-related
systemic effects and co-morbidity as use-cases thus
grounding the methodology in real-world applications. In
both use-cases we were able to identify candidate biomar-
kers that may help characterizing COPD heterogeneity,
and developed models with the potential to be considered
in future Clinical Decision Support Systems (e.g. co-mor-
bidity prevention and prognosis among other objectives).
Throughout the project we identified several key factors
that are currently limiting the clinical applicability of our
approach: the most important ones were data availability,
normalization of frameworks (e.g. ICD codes in co-mor-
bidity) and the necessity of broader and optimized experi-
mental designs (e.g. the inclusion of co-morbidity
information in genomic studies).
In conclusion, we consider that the first steps to bridge
the gap between basic research and clinical practice are
built, however further steps are required to complete the
path. To exploit the full potential of our results, future fol-
low-ups are required for statistical and clinical validation,
and once validated, predictive models (supported by longi-
tudinal studies) will make a strong case for clinical applica-
tions. Further considerations on challenges and future are
discussed in [57] on this Supplement.
We are at the juncture of a very exciting era, where Sys-
tems Medicine offers the possibility of a real connection
between research and clinical applications. While Synergy-
COPD may only represent a minor milestone along a long
road, we are convinced it is a relevant and instructive case.
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